复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)获FDA批准开展用于治疗胸腺癌的1期临床试验

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate, for the treatment of thymic carcinoma (TC) [1] Group 1 - The FDA has approved the clinical trial for HLX43, allowing the company to proceed with further clinical-related work [1] - The company plans to conduct clinical trials for thymic carcinoma in countries such as Australia, Japan, and the United States once conditions are met [1]